Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Our study will investigate inhalation therapy of NaCl 3% compared to standard therapy with no inhalation in the treatment of moderate to severe bronchiolitis. The impact on length of hospital stay will be analyzed.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Raphaelle Jaquet-Pilloud
• Collaborator: Swiss Foundation for the Health of Children and Adolescents

Criteria

Inclusion Criteria:

• children between ages 6 weeks to 24 months

• first episode of wheezing

• diagnosis of moderate to severe bronchiolitis: The patients are ranked as moderately to severely ill according to the Wang clinical severity score

Exclusion Criteria:

• Children with mild bronchiolitis (Wang score < 5)

• Children with pre-existent cardiac disease

• Children with clinically significant chronic respiratory disease

• Immunocompromised children

• Children with a gestational age at birth less than 34 weeks

• Children who received immunoprophylaxis therapy (i.e RSV immune globulin therapy)

• Children who received corticosteroid in any form in the preceding 2 weeks before presentation

• Children who received bronchodilators within 24 hours before presentation

• Children with critical illness at presentation requiring immediate admission to intensive care unit